CNR1 and Other metabolic disease: Despite this experience, there is still interest in the development of CB1 antagonism as a pharmacological tool for the treatment of metabolic disorders, however, with a better safety profile (Le Foll et al., 2009; Janero et al., 2011; Ward and Raffa, 2011; Kirilly et al., 2012).